Methods of Treating an Optic Disease in a Subject
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
1 . A method of regulating conveyance of light information from a retina to a central nervous system of a subject, the method comprising, administering to the subject at least two multifocal injections of a pharmaceutical composition comprising:
i) at least 100 units of a type A botulinum toxin, and
ii) a pharmaceutically acceptable carrier;
thereby regulating conveyance of light information from the retina to the central nervous system of the subject, wherein:
the regulating results in treating a local inflammatory disease in the subject.
2 . The method of claim 1 , wherein the at least two multifocal injections are at least one selected from the group consisting of transcutaneous, percutaneous, subcutaneous, intraperitoneal, transdermal, intramuscular and intraosseous.
3 . A method of regulating conveyance of light information from a retina to a central nervous system of a subject, the method comprising, administering to the subject a pharmaceutical composition comprising:
i) an effective amount of a botulinum toxin, and
ii) a pharmaceutically acceptable carrier;
thereby regulating conveyance of light information from the retina to the central nervous system of the subject.
4 . The method of claim 3 , wherein the regulating results in treating a light-induced circadian rhythm disorder in the subject.
5 . The method of claim 3 , wherein the regulating results in treating a local inflammatory disease in the subject.
6 . The method of claim 3 , wherein the subject further suffers from an ocular surface disease.
7 . The method of claim 5 , wherein the subject further suffers from an ocular surface disease.
8 . The method of claim 7 , wherein the pharmaceutical composition is formulated in the form of an eye drop.
9 . The method of claim 3 , wherein the botulinum toxin is a type A botulinum toxin.
10 . The method of claim 9 , wherein the botulinum toxin type A is from a Hall strain Clostridium botulinum.
11 . The method of claim 3 , wherein the botulinum toxin is a type B botulinum toxin.
12 . The method of claim 5 , wherein the botulinum toxin is a type A botulinum toxin.
13 . The method of claim 12 , wherein the botulinum toxin type A is from a Hall strain Clostridium botulinum.
14 . The method of claim 5 , wherein the botulinum toxin is a type B botulinum toxin.
15 . The method of claim 1 , wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of: an excipient; a surface active agent; a dispersing agent; an inert diluent; a granulating agent; a disintegrating agent; a binding agent; a lubricating agent; a preservative; a physiologically degradable material; an aqueous vehicle; a solvent; an oily vehicle; a suspending agent; a wetting agent; an emulsifying agent; a demulcent; a buffer; a salt; a thickening agent; a filler; an antioxidant; a stabilizing agent; a pharmaceutically acceptable polymeric material; and a hydrophobic material.
16 . The method of claim 3 , wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of: an excipient; a surface active agent; a dispersing agent; an inert diluent; a granulating agent; a disintegrating agent; a binding agent; a lubricating agent; a preservative; a physiologically degradable material; an aqueous vehicle; a solvent; an oily vehicle; a suspending agent; a wetting agent; an emulsifying agent; a demulcent; a buffer; a salt; a thickening agent; a filler; an antioxidant; a stabilizing agent; a pharmaceutically acceptable polymeric material; and a hydrophobic material.
17 . The method of claim 5 , wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of: an excipient; a surface active agent; a dispersing agent; an inert diluent; a granulating agent; a disintegrating agent; a binding agent; a lubricating agent; a preservative; a physiologically degradable material; an aqueous vehicle; a solvent; an oily vehicle; a suspending agent; a wetting agent; an emulsifying agent; a demulcent; a buffer; a salt; a thickening agent; a filler; an antioxidant; a stabilizing agent; a pharmaceutically acceptable polymeric material; and a hydrophobic material.
18 . The method of claim 3 , wherein the administering is a transdermal administering.
19 . The method of claim 3 , wherein the administering comprises an injection.
20 . The method of claim 19 , wherein the administering comprises at least two injections.
21 . The method of claim 20 , wherein the at least two injections are multifocal injections.
22 . The method of claim 21 , wherein the multifocal injections are at least one selected from the group consisting of transcutaneous, percutaneous, subcutaneous, intraperitoneal, transdermal, intramuscular and intraosseous.
23 . The method of claim 19 , wherein from 1.25 units to 3,000 units of the botulinum toxin are injected.
24 . The method of claim 19 , wherein at least 100 units of the botulinum toxin are injected.
25 . The method of claim 23 , wherein the botulinum toxin is a type A botulinum toxin.
26 . The method of claim 24 , wherein the botulinum toxin is a type A botulinum toxin.